

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Ascletis Pharma Inc.

歌禮製藥有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 1672)

VOLUNTARY ANNOUNCEMENT

PROPOSED SHARE REPURCHASE UNDER THE REPURCHASE MANDATE

The board of directors (the “**Board**”) of Ascletis Pharma Inc. (the “**Company**”) hereby announces that it intends to exercise its powers under the general mandate (the “**Repurchase Mandate**”) to repurchase shares of the Company (the “**Shares**”) granted by the shareholders of the Company (the “**Shareholders**”) to the Board at the annual general meeting (the “**AGM**”) of the Company held on May 23, 2024 to repurchase Shares on the open market at appropriate timing. According to the Repurchase Mandate, the Company is allowed to repurchase a maximum of 101,275,800 Shares, being 10% of the total number of issued Shares (excluding treasury shares, if any) as at the date of the AGM (the “**Proposed Share Repurchase**”).

On July 1, 2024, the Board has decided to utilize the Repurchase Mandate and, subject to market conditions, repurchase Shares on the open market from time to time to use up to HK\$200 million in funds for the Proposed Share Repurchase.

The financial position of the Company is currently solid and healthy. The Board considers that the current trading price of the Shares does not reflect their intrinsic value. The Board believes the Proposed Share Repurchase could enhance the value of the Shares thereby improving the return to shareholders of the Company. In addition, the Board believes that the Proposed Share Repurchase reflects the Company’s confidence in its long term business prospects and growth potential of the Company, and would ultimately benefit the Company and is in the best interests of the Company and the shareholders of the Company as a whole.

The Proposed Share Repurchase will be funded by the Company’s existing available cash. No repurchases would be made in circumstances that would have a material adverse impact on the working capital positions of the Company. Under the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”), the actual repurchase price of each Share shall be no more than 5% higher than the average closing market price for the Shares over the 5 trading days immediately preceding each repurchase. The Company will conduct the Proposed Share Repurchase in compliance with the Repurchase Mandate, memorandum and articles of association of the Company, the Listing Rules, the Codes on Takeovers and Mergers and Share Buy-backs, the Companies Act of the Cayman Islands and all applicable laws and regulations to which the Company is subject to. The Proposed Share Repurchase shall not result in the number of the Shares held by the public falling below the relevant minimum percentage prescribed by the Listing Rules. The Company will subsequently cancel, hold in treasury, sell or transfer the repurchased Shares, if any, as deemed appropriate by the Board.

As at the date of this announcement, the Company has not repurchased any Shares under the Repurchase Mandate. Shareholders and potential investors should note that any repurchase may be done subject to market conditions and at the absolute discretion of the Board. There is no assurance of the timing, quantity or price of any repurchase or whether or not the Company will make any repurchase. **Shareholders and potential investors should therefore exercise caution when dealing in the Shares.**

By order of the Board
Asclepis Pharma Inc.
歌禮製藥有限公司
Jinzi Jason WU
Chairman

Hangzhou, the People's Republic of China
July 2, 2024

As at the date of this announcement, the Board of Directors of the Company comprises Dr. Jinzi Jason WU and Mrs. Judy Hejingdao WU, as executive Directors; Dr. Yizhen WEI, Mr. Jiong GU and Ms. Lin HUA, as independent non-executive Directors.